



HYMOVIS® Receives Permanent, Product-Specific J-Code from the Centers for Medicare and Medicaid Services (CMS)

PARSIPPANY, NJ.(BUSINESS WIRE)— Fidia Pharma USA Inc., a wholly owned subsidiary of Fidia Farmaceutici S.p.A. a worldwide leader in the research development and manufacturing of HA based products, has announced that the Center for Medicare & Medicaid Services ("CMS") has assigned its product HYMOVIS® a unique Healthcare Common Procedure Coding System ("HCPCS") code, or J-Code. The new J-Code provides reimbursement coding to healthcare professionals that administer HYMOVIS® and becomes effective on January 1, 2017.

"HYMOVIS® is a true innovation in HA viscosupplementation. Its unique molecular structure results in enhanced biomechanical properties and long-lasting efficacy, all in a convenient two-dose regimen." said Aldo Donati, President, Fidia Pharma USA Inc. "We are excited that the CMS has issued a unique J-Code for HYMOVIS®. This will facilitate reimbursement and ensure greater access to this unique viscoelastic technology."

HYMOVIS® is a highly viscoelastic, non-crosslinked hydrogel bioengineered using a proprietary process that increases lubrication and shock absorption properties and results in a natural hyaluronan similar to the hyaluronan found in the synovial fluid present in human joints. The formulation allows this unique molecule to recover its original structure, even after repetitive mechanical stress. Due to reversible hydrophobic interactions, the non-crosslinked HYMOVIS® has increased elasticity, viscosity and residence time in the joint.*

About Fidia Pharma USA Inc.

Fidia Pharma USA Inc is a wholly-owned subsidiary of Italian pharmaceutical manufacturer Fidia Farmaceutici S.p.A., an established leader in the hyaluronic acid market segment. Fidia Pharma USA Inc. is focused on expanding Fidia's position in the U.S. and Canadian market, while upholding the company's mission to provide consumers with innovative products that offer quality, safety and performance. Fidia Pharma USA Inc. is headquartered in Parsippany, NJ. For more information, please visit www.fidiapharma.us.

About Fidia Farmaceutici S.p.A.

Fidia Farmaceutici S.p.A. is an Italian pharmaceutical company founded in 1946. It is a leader in research and marketing hyaluronic acid-based products, with several applications in the biomedical field, such as rheumatology, orthopaedics, surgery, wound care, tissue repair and dermo-aesthetics. Fidia Farmaceutici is part of the P&R Holding group. The company is located in Italy, with R&D facilities in Abano Terme (Padua) and Noto (Sicily). Fidia has more than 700 employees, and its revenue exceeds €250 million euros. Fidia Farmaceutici S.p.A.'s products are marketed in more than 100 countries, through wholly owned subsidiaries and a comprehensive network of international partnerships and distributors. Thanks to its investment in research, it has created a legacy of products with more than 600 patents to its name. For more information, please visit www.fidiapharma.com.

For more information, contact:

Fidia Pharma USA Inc.
Morris Corporate Center 1
Building C, 1st floor
300 Interpace Parkway
Parsippany, NJ 07054
1-973-507-5120
ckong@fdiapharma.us

HYMOVIS® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics.

HYMOVIS® is contraindicated in patients with known hypersensitivity to hyaluronate preparations or gram positive bacterial proteins or patients with infections/skin diseases in the area of the injection site/joint. The safety and effectiveness of HYMOVIS® has not been tested in pregnant women, nursing mothers or children. See package insert for full prescribing information including adverse events, warnings, precautions, and side effects at www.Hymovis.com.

HYMOVIS and HYADD 4 are registered trademarks of Fidia Farmaceutici S.p.A., Abano, Terme, Italy.
©2017 Fidia Pharma USA Inc., Parsippany, NJ, a wholly owned subsidiary of Fidia Farmaceutici S.p.A.
FID445-11.2016

*Preclinical studies may not be indicative of human clinical outcomes.

Rx Only
